With primary facilities in Ohio and a smaller presence in Boston, MA, Thermalin Diabetes Inc. is developing a portfolio of insulin analogs to address both the fast-acting and long-acting insulin markets. Founded on compounds invented at Case Western Reserve Medical School, Thermalin's therapeutic proteins are designed to address medical needs related to diabetes and its complications. The firm's new forms of insulin, based on novel protein designs and formulations, will enable insulin-dependent type 1 and type 2 diabetes patients to achieve improved glycemic control and quality of life, while reducing the costs of diabetes-related illnesses to the healthcare system. preclinical-stage The engineered insulin analogs under development include a ultra-rapid-acting insulin, glucose-responsive insulin, a once-a-week insulin patch, and insulin that doesn't need refrigeration.
